Xin Lu

TL;DR: It is demonstrated that apoptosis resulting from a loss in MCL-1 function requires expression of the proapoptotic protein BAK, and substantial synergy is demonstrated between navitoclax and Mcl-1 siRNA, the direct M CL-1 inhibitor A-1210477, or the indirect MCL -1 inhibitor flavopiridol, highlighting the therapeutic potential for inhibiting BCL-XL and MCL,1 in breast cancer.

TL;DR: It is shown that ABBV-075 efficiently triggers apoptosis in acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells, and in vivo combination studies uncovered surprising benefits of low doses of ABBv-075 coupled with bortezomib and azacitidine treatment, despite the lack of in vitro synergy between ABB V-075 and these agents.

TL;DR: The successful implementation of 3D models will require phenotypic characterization to verify the relevance of applying these models for drug development, as a limited number of signal transduction pathways operational in vivo were better represented by 3D than by 2D cultures in vitro.

TL;DR: Methods for assessing EGFR mRNA expression, RNA sequencing and RT-PCR, but not protein expression, can be used as surrogates for EGFR amplification (FISH) in GBM, providing enhanced understanding of available screening options for patients, which may help guide EGFR-targeted therapeutic approaches.

TL;DR: The hypothesis of targeting type 1 IFN to the tumor microenvironment may enhance effector T cell functions for anti-tumor immune response is supported.